Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prostate Cancer in Firemen: Is There a Diagnostic Bias?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03896178
Recruitment Status : Not yet recruiting
First Posted : March 29, 2019
Last Update Posted : April 2, 2019
Sponsor:
Collaborators:
Cancer Registry of Norway
Extrastiftelsen
The National Institute of Occupational Health
Norwegian Confederation of Trade Unions
Fagforbundet
Gjensidige Foundation
Norwegian Cancer Society
Norwegian Firefighters Fight Cancer
Norwegian Labour Inspection Authority
Information provided by (Responsible Party):
Jarle Jakobsen, Cancer Registry of Norway

Brief Summary:
Firefighters, police, military personnel and pilots are all shown to have a higher incidence of prostate cancer than the general population. A possible explanation for this is that these four groups of employees need regular mandatory health-checkups. If these checkups increase the chances of having a PSA or DRE performed one could expect the workers in question to have a higher probability than the general population of being diagnosed with prostate cancer. If this is the case the four groups should have cancers that are lower grade and have better survival. The investigators wish to examine this by comparing the four groups with a control group made up of all other workers with regards to prognostic factors at the time of diagnosis and survival rates. This will be done by extracting data from the Cancer Registry of Norway, coupled with employment data from Statistics Norway. This study is also a part of a project on cancer in firefighters. If the prostate cancers in firefighters differ significantly from the other three specified groups, this could point to an exposure specific for firefighters, e.g. fire smoke, as an etiologic factor.

Condition or disease Intervention/treatment
Prostate Cancer Other: None, observational study

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 160000 participants
Observational Model: Case-Only
Time Perspective: Other
Target Follow-Up Duration: 60 Years
Official Title: Aggressiveness of Prostate Cancer in Firefighters, Police Officers, Military Personnel and Pilots as Compared to the General Population: Is There a Diagnostic Bias?
Estimated Study Start Date : September 1, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Group/Cohort Intervention/treatment
Firefighters Other: None, observational study
None, observational study

Pilots Other: None, observational study
None, observational study

Police Other: None, observational study
None, observational study

Military personnel Other: None, observational study
None, observational study

Controls
Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
Other: None, observational study
None, observational study




Primary Outcome Measures :
  1. Cause-specific mortality rate for prostate cancer [ Time Frame: From January 1st 1960 until December 31st 2018 ]

Secondary Outcome Measures :
  1. TNM staging [ Time Frame: January 1st 1960 until December 31st 2018 ]
  2. Gleason score [ Time Frame: January 1st 1960 until December 31st 2018 ]
    Score based on microscopic appearance of prostate cancer tissue. Sum of two scores, each ranging from 1-5 (only whole numbers), meaning the final score ranges from 2-10. A higher score is associated with a more aggressive/less differentiated tumor. It is normal to group scores 2-6 together in >7. It is also normal to differentiate between 7 (4+3) (worse), and 7 (3+4) (better).

  3. PSA at time of diagnosis [ Time Frame: January 1st 1960 until December 31st 2018 ]
  4. Functional status at time of diagnosis (WHO classification) [ Time Frame: January 1st 1960 until December 31st 2018 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All men registered in the Cancer Registry of Norway with prostate cancer. Analysis of firefighters, pilots, police, military personnel and a matched group of other workers.
Criteria

Inclusion Criteria:

  • All cases of prostate cancer as registered by the Cancer Registry of Norway

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03896178


Locations
Layout table for location information
Norway
Cancer Registry of Norway Active, not recruiting
Oslo, Norway, 0304
Sponsors and Collaborators
Oslo University Hospital
Cancer Registry of Norway
Extrastiftelsen
The National Institute of Occupational Health
Norwegian Confederation of Trade Unions
Fagforbundet
Gjensidige Foundation
Norwegian Cancer Society
Norwegian Firefighters Fight Cancer
Norwegian Labour Inspection Authority

Additional Information:

Layout table for additonal information
Responsible Party: Jarle Jakobsen, PhD-student, Cancer Registry of Norway
ClinicalTrials.gov Identifier: NCT03896178     History of Changes
Other Study ID Numbers: 2019/542
First Posted: March 29, 2019    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases